These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24014508)

  • 1. Neurobehavioral features and natural history of juvenile neuronal ceroid lipofuscinosis (Batten disease).
    Adams HR; Mink JW;
    J Child Neurol; 2013 Sep; 28(9):1128-36. PubMed ID: 24014508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methodology of clinical research in rare diseases: development of a research program in juvenile neuronal ceroid lipofuscinosis (JNCL) via creation of a patient registry and collaboration with patient advocates.
    de Blieck EA; Augustine EF; Marshall FJ; Adams H; Cialone J; Dure L; Kwon JM; Newhouse N; Rose K; Rothberg PG; Vierhile A; Mink JW;
    Contemp Clin Trials; 2013 Jul; 35(2):48-54. PubMed ID: 23628560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuropsychological symptoms of juvenile-onset batten disease: experiences from 2 studies.
    Adams HR; Kwon J; Marshall FJ; de Blieck EA; Pearce DA; Mink JW
    J Child Neurol; 2007 May; 22(5):621-7. PubMed ID: 17690071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac involvement in juvenile neuronal ceroid lipofuscinosis (Batten disease).
    Ostergaard JR; Rasmussen TB; Mølgaard H
    Neurology; 2011 Apr; 76(14):1245-51. PubMed ID: 21464428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vision loss in juvenile neuronal ceroid lipofuscinosis (CLN3 disease).
    Ouseph MM; Kleinman ME; Wang QJ
    Ann N Y Acad Sci; 2016 May; 1371(1):55-67. PubMed ID: 26748992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Profound infantile neuroretinal dysfunction in a heterozygote for the CLN3 genetic defect.
    de los Reyes E; Dyken PR; Phillips P; Brodsky M; Bates S; Glasier C; Mrak RE
    J Child Neurol; 2004 Jan; 19(1):42-6. PubMed ID: 15032383
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Timing of cognitive decline in CLN3 disease.
    Kuper WFE; van Alfen C; Rigterink RH; Fuchs SA; van Genderen MM; van Hasselt PM
    J Inherit Metab Dis; 2018 Mar; 41(2):257-261. PubMed ID: 29392585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A novel c.1135_1138delCTGT mutation in CLN3 leads to juvenile neuronal ceroid lipofuscinosis.
    Drack AV; Miller JN; Pearce DA
    J Child Neurol; 2013 Sep; 28(9):1112-6. PubMed ID: 23877479
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Remote Assessment of Cognitive Function in Juvenile Neuronal Ceroid Lipofuscinosis (Batten disease): A Pilot Study of Feasibility and Reliability.
    Ragbeer SN; Augustine EF; Mink JW; Thatcher AR; Vierhile AE; Adams HR
    J Child Neurol; 2016 Mar; 31(4):481-7. PubMed ID: 26336202
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Juvenile neuronal ceroid lipofuscinosis and education.
    von Tetzchner S; Fosse P; Elmerskog B
    Biochim Biophys Acta; 2013 Nov; 1832(11):1894-905. PubMed ID: 23470553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Klüver-Bucy syndrome in juvenile neuronal ceroid lipofuscinosis.
    Lanska DJ; Lanska MJ
    J Child Neurol; 1994 Jan; 9(1):67-9. PubMed ID: 8151088
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variant late infantile neuronal ceroid lipofuscinosis because of CLN1 mutations.
    Simonati A; Tessa A; Bernardina BD; Biancheri R; Veneselli E; Tozzi G; Bonsignore M; Grosso S; Piemonte F; Santorelli FM
    Pediatr Neurol; 2009 Apr; 40(4):271-6. PubMed ID: 19302939
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Standardized assessment of seizures in patients with juvenile neuronal ceroid lipofuscinosis.
    Augustine EF; Adams HR; Beck CA; Vierhile A; Kwon J; Rothberg PG; Marshall F; Block R; Dolan J; Mink JW;
    Dev Med Child Neurol; 2015 Apr; 57(4):366-71. PubMed ID: 25387857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Females experience a more severe disease course in Batten disease.
    Cialone J; Adams H; Augustine EF; Marshall FJ; Kwon JM; Newhouse N; Vierhile A; Levy E; Dure LS; Rose KR; Ramirez-Montealegre D; de Blieck EA; Mink JW
    J Inherit Metab Dis; 2012 May; 35(3):549-55. PubMed ID: 22167274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A clinical rating scale for Batten disease: reliable and relevant for clinical trials.
    Marshall FJ; de Blieck EA; Mink JW; Dure L; Adams H; Messing S; Rothberg PG; Levy E; McDonough T; DeYoung J; Wang M; Ramirez-Montealegre D; Kwon JM; Pearce DA
    Neurology; 2005 Jul; 65(2):275-9. PubMed ID: 16043799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pathogenesis and therapies for infantile neuronal ceroid lipofuscinosis (infantile CLN1 disease).
    Hawkins-Salsbury JA; Cooper JD; Sands MS
    Biochim Biophys Acta; 2013 Nov; 1832(11):1906-9. PubMed ID: 23747979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hippocampal volumes in juvenile neuronal ceroid lipofuscinosis: a longitudinal magnetic resonance imaging study.
    Tokola AM; Salli EK; Åberg LE; Autti TH
    Pediatr Neurol; 2014 Feb; 50(2):158-63. PubMed ID: 24411222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revelation of a novel CLN5 mutation in early juvenile neuronal ceroid lipofuscinosis.
    Cannelli N; Nardocci N; Cassandrini D; Morbin M; Aiello C; Bugiani M; Criscuolo L; Zara F; Striano P; Granata T; Bertini E; Simonati A; Santorelli FM
    Neuropediatrics; 2007 Feb; 38(1):46-9. PubMed ID: 17607606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First African-American child with juvenile neuronal ceroid lipofuscinosis.
    Inan C; Wong D; Wisniewski KE; Rose AL; Musarella MA
    Am J Med Genet; 1998 Oct; 79(5):335-6. PubMed ID: 9779797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Considerations for the treatment of infantile neuronal ceroid lipofuscinosis (infantile Batten disease).
    Sands MS
    J Child Neurol; 2013 Sep; 28(9):1151-8. PubMed ID: 24014510
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.